Tetanus toxoid (TT) (TT)

Tetanus toxoid is a formaldehyde-inactivated derivative of tetanospasmin, the potent neurotoxin produced by the bacterium Clostridium tetani (PubChem, 2024). It serves as the primary antigenic component in vaccines designed to provide active immunity against tetanus, a severe neurological disease characterized by painful muscle spasms and potential respiratory failure (WHO, 2023). Upon administration, the toxoid stimulates the host's immune system to produce protective IgG antitoxin antibodies that neutralize the native toxin if the individual is later exposed to the pathogen. Beyond its role in primary vaccination, tetanus toxoid is frequently utilized as a carrier protein in conjugate vaccines, such as those for Haemophilus influenzae type b, to enhance the immunogenicity of polysaccharide antigens in young children (CDC, 2024). Additionally, it is commonly employed as a recall antigen in clinical immunology to assess the integrity of a patient's cell-mediated immune response through delayed-type hypersensitivity skin testing.

Other names

Tetanus anatoxinInactivated tetanus toxinTetanus vaccine antigen

Tetanus toxoid acts as an immunogen that triggers a B-cell mediated immune response, leading to the production of neutralizing IgG antibodies (antitoxins). These antibodies bind to the C-fragment of the tetanospasmin toxin, preventing its uptake into inhibitory interneurons of the spinal cord and subsequent blockade of neurotransmitter release (StatPearls, 2023; CDC, 2024).